4510-12-7

Basic information

• Product Name: Benzoic acid, 4-hydrazino-, Methyl ester
• Synonyms: Benzoic acid, 4-hydrazino-, Methyl ester;Methyl 4-hydrazinylbenzoate;4-Methoxycarbonylphenylhydrazine
• CAS NO: 4510-12-7
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1772
• Mol File: 4510-12-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 4-hydrazino-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-hydrazino-, Methyl ester(4510-12-7)
• EPA Substance Registry System: Benzoic acid, 4-hydrazino-, Methyl ester(4510-12-7)

Safety Data

• Hazardous Substances Data: 4510-12-7(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 4-hydrazino-, methyl ester is a chemical compound with the molecular formula C8H10N2O2. It is a methyl ester derivative of 4-hydrazinobenzoic acid, and its structure includes a benzene ring with a carboxylic acid group and a hydrazine group attached to it. Benzoic acid, 4-hydrazino-, methyl ester is often used in organic synthesis and medicinal chemistry as a starting material for the synthesis of other compounds, particularly in the development of pharmaceuticals. It has also been studied for its potential antimicrobial and antiproliferative properties. Benzoic acid, 4-hydrazino-, methyl ester may also have applications in the development of pesticides or as a chemical intermediate in various industries.

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 619-45-4 4-methoxycarbonyl aniline 
• 67-56-1 methanol 
• 619-67-0 4-Hydrazinobenzoic acid 

Downstream Products

• 1147893-83-1 methyl 4-(1-(2-(6-methylpyridin-3-yl)ethyl)hydrazinyl)benzoate 
• 201530-41-8 deferasirox 
• 1414867-90-5 methyl 4-(3-(2-hydroxyphenyl)-5-(2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)-1H-1,2,4-triazol-1-yl)benzoate 
• 1414867-91-6 4-(5-(2-((4-boronobenzyl)oxy)phenyl)-3-(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid 
• 1414867-92-7 4-(3-(2-hydroxyphenyl)-5-(2-((4-(3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)benzyl)oxy)phenyl)-1H-1,2,4-triazol-1-yl)benzoic acid 
• 1266741-05-2 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid methyl ester 
• 1160437-40-0 methyl 3-phenyl-1H-indole-5-carboxylate 
• 1027232-57-0 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-1-pyrazolyl)benzoic acid methyl ester 

Relevant articles and documents

The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjic domain-containing histone demethylases

Fe(II)- A nd 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are "epigenetic eraser" enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set of clinically used iron chelators and report that they potently inhibit JMJD2A (KDM4A) in vitro. Mode of action investigations revealed that one compound, deferasirox, is a bona fide active site-binding inhibitor as shown by kinetic and spectroscopic studies. Synthesis of derivatives with improved cell permeability resulted in significant upregulation of histone trimethylation and potent cancer cell growth inhibition. Deferasirox was also found to inhibit human 2OG-dependent hypoxia inducible factor prolyl hydroxylase activity. Therapeutic effects of clinically used deferasirox may thus involve transcriptional regulation through 2OG oxygenase inhibition. Deferasirox might provide a useful starting point for the development of novel anticancer drugs targeting 2OG oxygenases and a valuable tool compound for investigations of KDM function.

The indole skeleton-containing [...] steroidal saponin aglycone derivatives, its preparation method and application

The invention discloses an indole skeleton-containing dihydropyrazolhydroxamic acid steroid sapogenin derivative, and a preparation method and an application thereof. The structure of the indole skeleton-containing dihydropyrazolhydroxamic acid steroid sapogenin derivative is represented by formula VIII shown in the specification; and in the formula VIII, R1 is selected from H and CH3, R2 is selected from H and CH3, R3 is selected from H and F, and R4 is selected from H and CH3. The derivative has an obvious inhibition effect on human breast cancer cells (MCF-7), cervical carcinoma cells (HeLa), lung cancer cells (A549) and liver cancer cells (HepG2), has same or better cytotoxicity on human renal epithelial cells (293T) than positive control drug Celecoxib, and can be used to prepare antitumor drugs. The derivative has the advantages of good bioactivity, high selectivity, low toxicity and short residual life.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.